Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 2.1935 USD -2.94% Market Closed
Market Cap: 97.1m USD
Have any thoughts about
Adagene Inc?
Write Note

Adagene Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adagene Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Adagene Inc
NASDAQ:ADAG
Operating Expenses
-$41.8m
CAGR 3-Years
2%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Expenses
-ÂĄ23.5B
CAGR 3-Years
-22%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Expenses
-ÂĄ3.1B
CAGR 3-Years
-41%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Operating Expenses
-ÂĄ954.2m
CAGR 3-Years
-6%
CAGR 5-Years
2%
CAGR 10-Years
-19%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Expenses
-ÂĄ4.6B
CAGR 3-Years
-29%
CAGR 5-Years
-28%
CAGR 10-Years
-30%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Expenses
-ÂĄ649m
CAGR 3-Years
-53%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
No Stocks Found

Adagene Inc
Glance View

Market Cap
97.1m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
0.924 USD
Overvaluation 58%
Intrinsic Value
Price

See Also

What is Adagene Inc's Operating Expenses?
Operating Expenses
-41.8m USD

Based on the financial report for Dec 31, 2023, Adagene Inc's Operating Expenses amounts to -41.8m USD.

What is Adagene Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-17%

Over the last year, the Operating Expenses growth was 55%. The average annual Operating Expenses growth rates for Adagene Inc have been 2% over the past three years , -17% over the past five years .

Back to Top